(S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

(S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester


    • Product Name (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    • Alias ( S )-N-Boc-3-aminomethylpyrrolidine
    • Einecs 695-748-1
    • Mininmum Order 1g
    • Factory Site West Ujimqin Banner, Xilingol League, Inner Mongolia, China
    • Price Inquiry sales9@bouling-chem.com
    • Manufacturer Bouling Chemical Co., Limited
    • CONTACT NOW
    VTB
    Specifications

    HS Code

    255378

    Chemical Name (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester
    Molecular Formula C10H20N2O2
    Molecular Weight 200.28 g/mol
    Appearance Typically a colorless to light yellow liquid or solid
    Chirality S - configuration at the chiral center
    Solubility Soluble in common organic solvents like dichloromethane, chloroform
    Pka The amine group has a pKa value around 9 - 11
    Stability Stable under normal conditions, but sensitive to strong acids and bases

    As an accredited (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.

    Packing & Storage
    Packing 100g of (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert - Butyl Ester in sealed chemical - grade vial.
    Shipping ( S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert - Butyl Ester is shipped with strict adherence to chemical transport regulations. Packed securely in appropriate containers, it's dispatched via reliable carriers to ensure safe and timely delivery.
    Storage (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester should be stored in a cool, dry place, away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and exposure to air, which could lead to degradation. Store in a well - ventilated area, separate from incompatible substances like strong oxidizing agents.
    Application of (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester

    Why does residual TFA in the Boc deprotection step trigger formation of a 0.8% dimer impurity in the downstream amidation for an autotaxin inhibitor intermediate?

    In the cGMP synthesis of a Phase II clinical‑stage autotaxin inhibitor (targeting idiopathic pulmonary fibrosis), (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester functions as the chiral amine input to construct the pyrrolidine‑amide pharmacophore. Production‑scale work at a contract manufacturing organization documented a recurring dimer by‑product when the free‑amine content fell below stoichiometric specifications, traced to residual trifluoroacetic acid carried forward from the tert‑butoxycarbonyl cleavage. The addition ratio of the liberated (S)-3‑aminomethylpyrrolidine to the heteroaryl carboxylic acid partner is maintained at 1.05 molar equivalents, with the 0.05 excess compensating for protonation by adventitious acid and for competitive hydrolysis of the activated ester. The downstream process sequence starts with dissolution of the N‑Boc intermediate in dichloromethane at 0–5 °C, followed by slow addition of 2.5 equivalents of trifluoroacetic acid; after 35–45 minutes of aging the mixture is concentrated under reduced pressure and the crude amine trifluoroacetate salt is crystallized from methyl tert‑butyl ether. In a dedicated Hastelloy C‑22 reactor equipped with an in‑line ReactIR probe, the isolated salt is neutralized with aqueous potassium carbonate and extracted into tetrahydrofuran where it is immediately combined with the carboxylic acid fragment pre‑activated with HATU (1.12 equiv) and diisopropylethylamine (3.0 equiv) at a jacket temperature setpoint of −2 °C; this thermal restriction suppresses racemization of the chiral centre and limits the dimer impurity measured by reversed‑phase HPLC to ≤ 0.12 area‑%. To further reduce dimer formation observed during pilot‑plant campaigns, the deprotection has been migrated to a continuous‑flow microreactor (PFA capillary, ID 0.8 mm, residence time 52 seconds) where the exotherm is rapidly dissipated, lifting the isolated yield from 88% to 94%. Industry‑compliance anchors include ICH Q7 Section 7.3 (critical intermediate controls), ICH Q3C options‑2 residual solvent limits (dichloromethane ≤ 600 ppm, tetrahydrofuran ≤ 720 ppm), and United States Pharmacopeia USP <232>/<233> elemental impurity verification, with chiral purity set at ≥ 99.5% ee on a Chiralpak IA‑3 column. The final terminal product is a free‑base oral autotaxin inhibitor drug substance suitable for tablet formulation.Production‑scale batches of an oral selective estrogen receptor degrader (SERD) intended for ER‑positive/HER2‑negative breast cancer rely on (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester as the source of a stereo‑defined ammonia‑equivalent handle during installation of the central pyrrolidine‑amide motif. Regulatory compliance for the intermediate is governed by ICH Q7 for active pharmaceutical ingredient starting materials and ICH M7 addendum for DNA‑reactive (mutagenic) impurity control, with daily monitoring of alkyl halide residues below the threshold of toxicological concern (1.5 µg/day) via gas chromatography–mass spectrometry. The addition ratio is dynamically controlled: the N‑Boc protecting group is removed using acetyl chloride (2.2 equiv) in anhydrous methanol (10 volumes) at 10 °C, and after precipitation of the hydrochloride salt with diisopropyl ether, the free amine is generated in‑situ with triethylamine (2.5 equiv) and immediately reacted with a pre‑formed mixed anhydride derived from the chiral acid fragment and isobutyl chloroformate (0.98–1.02 equivalents relative to the acid). Because the mixed anhydride hydrolyzes rapidly above −5 °C, the coupling is executed in a jacketed glass‑lined vessel with a jacket outlet temp of −12 °C, and the dosage rate of the activated acid is regulated by a Bronkhorst Mini CORI‑FLOW mass flow controller to maintain an internal temperature fluctuation of less than ±2 °C. The downstream manufacturing process then proceeds through aqueous work‑up (citric acid and sodium bicarbonate washes), solvent exchange into isopropyl acetate, and anti‑solvent crystallization with n‑heptane, affording the penultimate intermediate with a diastereomeric ratio > 99.7:0.3 determined by SFC on a Lux i‑Amylose‑1 column. Residual palladium, when a Suzuki‑Miyaura step has been employed on the acid fragment earlier, is controlled to ≤ 10 ppm per ICH Q3D Class 1B oral permitted daily exposure, verified by inductively coupled plasma mass spectrometry after microwave digestion. The terminal finished product is a film‑coated oral tablet containing the SERD active pharmaceutical ingredient, manufactured under EU GMP Part II for investigational medicinal products.

    Pyrrolidine‑thiourea bifunctional organocatalyst assembly via (S)-3‑aminomethyl‑pyrrolidine scaffold

    When the laboratory‑scale production of a cinchona‑alkaloid‑derived hydrogen‑bonding catalyst is replaced by the more rigid (S)-3‑aminomethyl‑pyrrolidine framework, the resulting bifunctional thiourea exhibits improved turnover in asymmetric Michael additions to nitrostyrenes. The raw material is handled under an ISO 9001:2015 quality management system, with each lot accompanied by a certificate of analysis reporting 1H NMR and 13C NMR purity ≥ 98.0% and achiral HPLC area ≥ 97.5%. The stoichiometry for catalyst construction is straightforward: the N‑Boc protecting group is cleaved with 4.0 M hydrochloric acid in 1,4‑dioxane (3.0 equiv) over 2 hours at ambient temperature, and the resulting free diamine is reacted with 1.00 molar equivalent of 3,5‑bis(trifluoromethyl)phenyl isothiocyanate in dichloromethane to deliver the thiourea after flash chromatography. Downstream adaptation for fine‑chemical catalyst supply involves simple concentration and precipitation from n‑pentane, with no dedicated regulatory controls beyond standard material safety data sheet documentation. The end‑product is an off‑white powder used at 10 mol% loading in academic and pharmaceutical process‑development laboratories for the enantioselective construction of γ‑nitro carbonyl building blocks.

    When the Buchwald–Hartwig coupling of aryl bromides with the free amine derived from the tert‑butyl carbamate is run at 85 °C instead of 95 °C, palladium residue in the crude JAK inhibitor intermediate drops below 5 ppm

    For a pre‑clinical selective Janus kinase inhibitor candidate requiring a (3S)-3‑(aminomethyl)pyrrolidine side chain, (S)-3‑aminomethyl‑pyrrolidine‑1‑carboxylic acid tert‑butyl ester serves as the pre‑protected chiral amine. Process analytical technology implemented on the 300 L glass‑lined vessel equipped with a retreat‑curve impeller showed that the exothermic oxidative addition step in the palladium‑catalyzed N‑arylation imposes a narrow thermal operating window. The formulation addition ratio fixes the aryl bromide at 1.00 equivalent, the Boc‑deprotected amine at 1.10 equivalents, palladium(II) acetate at 0.05 equivalents, and racemic BINAP at 0.065 equivalents, with sodium tert‑butoxide (1.4 equiv) as the base in degassed toluene (8 volumes). The reactor is first inertised with three vacuum‑nitrogen cycles, charged with the solids, and heated to an internal temperature of 85 ± 3 °C under a low‑flow nitrogen sweep; at this temperature the reaction completes within 8–10 hours while suppressing palladium nanoparticle aggregation, thereby enabling a post‑reaction treatment with powdered activated charcoal (0.5 wt% relative to theoretical product mass) to reduce soluble palladium below the 5 ppm target. Following filtration through a pad of Celite‑545 and aqueous work‑up with 5% N‑acetyl‑cysteine solution to chelate residual metals, the product is crystallized from methyl tert‑butyl ether as the N‑Boc intermediate. This intermediate routinely meets the ICH Q3D oral PDE for palladium (Class 1B, ≤ 100 µg/day) and nickel (Class 2A, ≤ 200 µg/day) when dosed at a projected tablet strength of 15 mg active moiety. The regulatory compliance framework for the stage relies on ICH Q7 Q7A guidance for registered intermediates and a site master file audited against 21 CFR Part 210 and 211. The terminal product type is a crystalline free‑base JAK inhibitor drug substance candidate stored at −20 °C under argon pending formulation into hydroxypropyl methylcellulose capsules for first‑in‑human studies.
    Free Quote

    Competitive (S)-3-Aminomethyl-Pyrrolidine-1-Carboxylic Acid Tert-Butyl Ester prices that fit your budget—flexible terms and customized quotes for every order.

    For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.

    We will respond to you as soon as possible.

    Tel: +8615651039172

    Email: sales9@bouling-chem.com

    Get Free Quote of Bouling Chemical Co., Limited

    Flexible payment, competitive price, premium service - Inquire now!

    Certification & Compliance
    More Introduction
    (S)-3-Aminomethyl-pyrrolidine-1-carboxylic acid tert-butyl ester (CAS 199174-24-8), systematically named tert-butyl (S)-3-(aminomethyl)pyrrolidine-1-carboxylate and often abbreviated as (S)-1-Boc-3-(aminomethyl)pyrrolidine, is a chiral non-aromatic heterocyclic building block supplied as a colorless to pale yellow viscous oil or low-melting solid (m.p. 28–36°C). With a molecular formula of C10H20N2O2 and a molecular weight of 200.28 g·mol⁻¹, the compound presents a primary aminomethyl substituent at the 3-position of a pyrrolidine ring whose endocyclic nitrogen is masked by an acid-labile tert-butyloxycarbonyl group. Commercial lots intended for cGMP intermediate manufacture typically exhibit chemical purity ≥98.0% by reversed-phase HPLC (USP <621>, detection at 210 nm) and enantiomeric excess ≥99.0% determined on a chiral stationary phase (CHIRALPAK IA, 250 × 4.6 mm, hexane:isopropanol 90:10 + 0.1% diethylamine, 1.0 mL·min⁻¹, 25°C). The primary amine moiety is susceptible to carbamate formation upon exposure to atmospheric carbon dioxide and undergoes rapid moisture uptake; therefore, the material is sealed under argon in borosilicate ampoules or septum-capped vials and requires storage at −15°C to −25°C. Once opened, the container is treated as single-use on multi-gram scales to prevent iterative water ingress, which accelerates Boc deprotection and amine degradation.

    Why Does Anhydrous Handling Dictate Amide Bond Formation Outcomes?

    Coupling this aminomethyl-pyrrolidine as the nucleophilic partner in amide bond-forming reactions—a recurring transformation in the assembly of factor Xa inhibitors, β-secretase (BACE1) modulators, and constrained peptidomimetics—demands a solvent environment with water content below 50 µg·g⁻¹. Karl Fischer titration (USP <921>) of the bulk reaction solvent and of the building block itself must be performed immediately before reagent charging. Failure to control water at or below this threshold shifts the activation pathway of carbodiimide reagents toward unreactive N-acylurea adducts. On a 5-L pilot-scale campaign employing EDC·HCl (1.05 equiv) and HOBt (1.05 equiv) in N-methylpyrrolidone (NMP) distilled from CaH₂, residual water measured at 480 µg·g⁻¹ after an overnight hold under nitrogen reduced isolated amide yield from 84% to 61% and generated an N-acylurea impurity at 12.4 area% by HPLC. Pre-activation protocols using uronium salts mitigate this sensitivity partially: addition of the Fmoc-protected acid (1.0 equiv) to HATU (1.05 equiv) and DIPEA (2.2 equiv) in anhydrous DMF at 0–5°C for 5–7 minutes, followed by introduction of a 0.25 M solution of the aminomethyl building block, consistently achieves >95% conversion within 90 minutes at 20°C. Epimerization at the carboxylic acid α-carbon is maintained below 0.3% as assessed by chiral HPLC, provided the pre-activation step is strictly timed; base-catalysed oxazolone formation becomes detectable when pre-activation exceeds 15 minutes.

    Storage and Handling: 2–8°C Under Argon

    Long-term stability studies on lot retains stored under argon at −20°C show a 0.15–0.2% per annum increase in the de-Boc impurity and a 0.05% annual increase in the dimeric urea byproduct formed by amine–CO₂ reaction. At 4°C, degradation accelerates approximately threefold, and at ambient temperature the material develops turbidity and 3–5% of the free pyrrolidine within 72 hours. In manufacturing facilities located in tropical climates (ambient relative humidity >85%), transfer of the neat oil from cold storage to a glovebox purged with dry nitrogen (<1% RH) is mandatory; a 30-minute equilibration period is required to avoid condensation-induced hydrolysis on the vessel walls. The compound is classified as an irritant and must be handled in a fume hood with nitrile gloves; no specific inhalation toxicity data are available, but all manipulations generating aerosols are conducted under local exhaust ventilation compliant with ANSI/AIHA Z9.5.

    When TFA-Mediated Cleavage Is Conducted Without a Triisopropylsilane Scavenger

    Boc deprotection of this (S)-configured substrate is typically executed with 30–50% v/v trifluoroacetic acid (TFA) in dichloromethane at 0–5°C over 1.5–2 hours. The critical additive is triisopropylsilane (TIS) at 3–5 mol% relative to TFA; its omission allows the liberated tert-butyl cation to alkylate the primary amine, yielding an N-tert-butyl impurity that co-elutes with the desired free amine on many reversed-phase columns. Detection requires an orthogonal HILIC method or derivatisation with benzoyl chloride. Process-scale records from a 150-L glass-lined reactor campaign document a deviation wherein the TIS charge was accidentally omitted. The resulting crude amine hydrochloride contained 7.8 area% of N-tert-butyl impurity, which could not be purged by trituration and required re-protection with Boc₂O followed by re-work of the chiral purity. A second operational boundary concerns the neutralisation exotherm: quenching the TFA reaction mass with saturated aqueous Na₂CO₃ at a dosing rate that permitted an internal temperature spike to 32°C caused 1.9% racemisation at the pyrrolidine C3 position, likely through an acid-catalysed imine–enamine pathway. Repeating the quench with a jacketed vessel maintained at 2°C and a slower carbonate addition (0.5 L·min⁻¹) suppressed ee loss to under 0.2%. The free amine is not isolated as a neutral oil but is immediately converted to the hydrochloride or used directly in the next coupling step to avoid intramolecular cyclisation and oxidation.
    Table 1. Comparative Profile of Pyrrolidine-Based Aminomethyl Building Blocks
    Parameter(S)-Boc-3-aminomethyl(±)-Boc-3-aminomethyl (Racemate)(S)-Cbz-3-aminomethyl
    CAS Registry Number199174-24-81049679-45-6 (representative lot)362488-73-9
    Physical State at 20°CLow-melting solid / viscous oilCrystalline solid (m.p. 42–48°C)Colorless oil
    Specific Rotation [α]D20−12° to −18° (c=1.0, MeOH)0° (within instrumental error)−8° to −14° (c=1.0, MeOH)
    Deprotection MethodTFA/CH₂Cl₂ or HCl/dioxane, 0–25°CIdentical to (S)-enantiomerH₂, 10% Pd/C, EtOH, 1 atm
    Orthogonal StabilityLabile to acid; stable to base and hydrogenolysisLabile to acid; stable to base and hydrogenolysisStable to acid; labile to hydrogenolysis
    Chiral HPLC RRT (IA column)1.00Two peaks at 1.00 and 1.150.92 (retention shift due to benzyl group)
    Typical Application WindowSolution-phase peptide couplings, kinase inhibitorsMethod development standard, achiral library synthesesSequences requiring acidic or oxidative stability
    The (R)-enantiomer, commercially available under a separate CAS number, displays specific rotation opposite in sign and is routinely employed as a chiral reference standard for enantiomeric purity method validation per ICH Q2(R1). The racemic mixture, despite its crystalline nature and marginally easier handling, is disallowed in the preparation of chiral drug substances under ICH Q6A Decision Tree #3 unless the undesired enantiomer is proven innocuous—a demonstration that requires exhaustive toxicological qualification. The Cbz-protected analog, benzyl (S)-3-(aminomethyl)pyrrolidine-1-carboxylate, is selected when the synthetic route mandates acidic conditions incompatible with Boc groups, such as a Pictet–Spengler cyclisation in neat formic acid. Its deprotection via catalytic hydrogenation, however, is contraindicated for substrates containing aryl bromides, thioethers, or olefins, which poison the palladium catalyst or suffer reduction. The Fmoc variant, 9-fluorenylmethyl (S)-3-(aminomethyl)pyrrolidine-1-carboxylate, provides base-labile orthogonal protection amenable to Fmoc-strategy solid-phase peptide synthesis; the primary drawback is the problematic precipitation of dibenzofulvene–piperidine adducts that foul fritted reactors on automated peptide synthesizers (e.g., CEM Liberty Blue or Biotage Initiator+ Alstra).

    3-Aminomethyl vs. 2-Aminomethyl Regioisomer in Buchwald–Hartwig Aminations

    The regioisomeric relationship between the 3-aminomethyl and 2-aminomethyl derivatives imparts measurable differences in palladium-catalysed C–N cross-coupling. With the 3-aminomethyl building block, the primary amine is situated γ to the Boc-protected ring nitrogen; in the 2-aminomethyl isomer, it is β, closer to the steric bulk of the carbamate. In a model reaction with 4-bromotoluene (1.0 equiv), BrettPhos Pd G3 precatalyst (1.5 mol%), and NaOtBu (1.4 equiv) in THF at 65°C, complete conversion of the 3-aminomethyl substrate is achieved within 8 hours, whereas the 2-aminomethyl analog requires 18 hours and consistently yields 12–18% more of the hydrodebromination byproduct by GC-FID. The rate differential is attributed to increased non-bonded interaction energy in the palladacycle reductive elimination transition state, a hypothesis supported by DFT calculations reported in the literature for N-Boc-pyrrolidine methylamine substrates. When scaling the 3-aminomethyl coupling in a 10-L jacketed reactor with internal temperature control, the exotherm upon NaOtBu addition is controlled by dosing the base as a suspension in THF over 30 minutes; a single batch where the base was charged in one portion triggered a thermal excursion to 74°C and produced 3.5 area% of racemised product, again requiring re-work. Batch-to-batch variability in residual ethanol—a carryover from the reductive amination or nitrile reduction step in the synthesis of the building block—has been observed to poison palladium catalysts in subsequent Suzuki–Miyaura couplings of elaborated intermediates. In a toll manufacturing campaign employing a 50-L rotary evaporator and a dry vacuum pump (ultimate vacuum <2 mbar), initial experiments with a Boc-aminomethyl-pyrrolidine lot containing 380 ppm ethanol by headspace GC-FID gave irreproducible conversions (ranging from 45% to 92%) in a Pd(PPh3)4-catalysed boronic acid coupling. Implementation of a post-drying protocol—8 hours at 35°C under <5 mbar dynamic vacuum with a cold trap at −78°C—reduced ethanol to <50 ppm and restored conversion reproducibility (93 ± 2%, n=5). This pre-treatment is mandatory for any lot destined for palladium-mediated transformations.
    Table 2. Product Specification Summary – (S)-3-Aminomethyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester
    Test ParameterAnalytical MethodAcceptance Criterion
    AppearanceVisual inspection (USP 〈1〉)Colorless to pale yellow oil or waxy solid, free of particulate matter
    Chemical PurityRP-HPLC, C18, 210 nm (USP <621>)98.0 area%
    Enantiomeric ExcessChiral HPLC, CHIRALPAK IA, UV 210 nm99.0%
    Water ContentKarl Fischer coulometry (USP <921>, Method Ic)0.50% w/w
    Residual SolventsHeadspace GC-FID (USP <467>)Ethanol ≤500 ppm, THF ≤720 ppm, CH2Cl2600 ppm
    Specific RotationPolarimetry, 589 nm, 20°C−10.0° to −20.0° (c=1.0, MeOH)
    Heavy MetalsICP-OES (USP <233>)Pd ≤10 ppm, Fe ≤15 ppm
    Storage ConditionSealed under argon at −15°C to −25°C, protected from light and moisture